arrow
G

Giuseppe Fornarini

IRCCS Ospedale Policlinico San Martino
H指数:34
被引数:4,579

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial

粪便菌群移植联合pembrolizumab和阿昔替尼治疗转移性肾细胞癌: 随机2期TACITO试验

2026-01-280
PRE
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

基于疾病体积的转移性激素敏感型前列腺癌最佳治疗方法: 系统评价和网络荟萃分析

2025-11-170
OA
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis

评估内脏疾病患者中转移性激素敏感性前列腺癌的治疗效果:一项系统评价和网络Meta分析

2025-07-100
OAAI
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience

真实世界结局与分子分型:肺转移性去势抵抗性前列腺癌患者的长期多中心研究经验

2025-06-010
OAAI
Immunohistochemical Prostate-specific Membrane Antigen (PSMA) Expression Patterns of Primary Prostate Cancer Tissue as a Determining Factor for Prostate Cancer Staging with PSMA Positron Emission Tomography/Computed Tomography

前列腺癌组织免疫组化前列腺特异性膜抗原(PSMA)表达模式作为PSMA正电子发射断层扫描/计算机断层扫描前列腺癌分期的决定因素

2025-04-290
PRE
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

G8老年综合评估筛查和Meet-URO评分在转移性肾细胞癌患者接受一线伊匹木单抗-纳武利尤单抗联合免疫治疗中的预后价值

2025-02-240
OA
Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with 223RaCl2: Ten Years of Clinical Experience
2025-01-310
OAAI
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials

定义 [177Lu] lu-psma放射性配体疗法在转移性去势抵抗性前列腺癌治疗中的地位: 临床试验的荟萃分析

2024-11-291
PRE
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

转移性尿路上皮癌患者铂类化疗和Avelumab维持后的Enfortumab Vedotin: 来自ARON-2EV研究的回顾性数据

2024-10-011
OAAI
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [18F]PSMA-1007 PET/CT

综合预测评分可解释 [18F]PSMA-1007 PET/CT成像的激素敏感性前列腺癌患者的骨局灶性摄取

2024-09-052
PRE
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

mRCC骨转移患者的钠水平和免疫治疗功效: Meet-Uro 15研究的子分析

2024-07-055
OAAI
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)

转移性肾细胞癌患者的国际多中心真实世界注册表-meet-uro 33研究 (REGAL研究)

2024-06-246
OAAI
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study)
2024-06-217
OAAI
The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition

与PSMA靶向示踪剂相关的非特异性骨吸收的同源性: 基于系统评价的定义

2024-06-1714
OAAI
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

接受免疫治疗的晚期肾细胞癌患者的肿瘤微环境分析 (Meet-URO 18研究)

2024-06-120
PRE
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
2024-05-150
OAAI